• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

刺猬信号通路抑制剂:在基底细胞癌治疗中的临床意义及耐药性

Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma.

作者信息

Habashy Suzanne, Jafri Aliya, Osman Hiba O, Thomas Neena E, Udekwe Somtochi, Heindl Stacey E

机构信息

Family Medicine/Dermatology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Biochemistry and Family Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

出版信息

Cureus. 2021 Mar 12;13(3):e13859. doi: 10.7759/cureus.13859.

DOI:10.7759/cureus.13859
PMID:33754119
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7971714/
Abstract

Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer and is on the rise. Most BCCs are benign; however, a very small percentage are locally advanced and metastatic. The pathway that normally regulates cell growth and proliferation is directed by the hedgehog pathway (HP). In BCC, it becomes over-stimulated due to genetic abnormalities. Treatments for BCC include local treatment by cryotherapy (liquid nitrogen), topical immunosuppression, surgery, or radiotherapy. Systemic treatment may be required in locally advanced lesions, metastatic BCC, or individuals who are inoperable. The systemic treatments of BCC act to inhibit the HP and are called hedgehog pathway inhibitors. The first one being vismodegib and the second sonidegib. Although these treatments have shown promising results, they have prominent side effects in almost all patients, with few patients having to discontinue the treatment. About 50% of patients did not respond to treatment from the beginning, some had partial responses, others had recurrence after discontinuing the drugs, and few had worsening of the disease. In this paper, we will explore the most common side effects, resistance, and different methods to overcome resistance to ensure the highest rate of cure for BCC.

摘要

基底细胞癌(BCC)是最常见的非黑色素瘤皮肤癌,且其发病率正在上升。大多数基底细胞癌是良性的;然而,极小比例的基底细胞癌会出现局部进展和转移。正常情况下调节细胞生长和增殖的途径由刺猬信号通路(HP)主导。在基底细胞癌中,由于基因异常,该通路会受到过度刺激。基底细胞癌的治疗方法包括冷冻疗法(液氮)局部治疗、局部免疫抑制、手术或放疗。对于局部进展性病变、转移性基底细胞癌或无法进行手术的个体,可能需要进行全身治疗。基底细胞癌的全身治疗旨在抑制刺猬信号通路,被称为刺猬信号通路抑制剂。第一种是维莫德吉,第二种是索尼德吉。尽管这些治疗已显示出有前景的结果,但几乎所有患者都会出现明显的副作用,少数患者不得不停止治疗。约50%的患者从一开始就对治疗无反应,一些患者有部分反应,另一些患者在停药后复发,还有少数患者病情恶化。在本文中,我们将探讨最常见的副作用、耐药性以及克服耐药性的不同方法,以确保基底细胞癌的治愈率最高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52e/7971714/329cddb5386b/cureus-0013-00000013859-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52e/7971714/329cddb5386b/cureus-0013-00000013859-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52e/7971714/329cddb5386b/cureus-0013-00000013859-i01.jpg

相似文献

1
Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma.刺猬信号通路抑制剂:在基底细胞癌治疗中的临床意义及耐药性
Cureus. 2021 Mar 12;13(3):e13859. doi: 10.7759/cureus.13859.
2
A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.对刺猬信号通路及维莫德吉在基底细胞癌治疗中作用的全面综述。
Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17.
3
Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.在治疗晚期基底细胞癌时,更换刺猬信号通路抑制剂及其他策略以应对耐药性。
Oncotarget. 2021 Sep 28;12(20):2089-2100. doi: 10.18632/oncotarget.28080.
4
Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.维莫德吉治疗基底细胞癌:ERIVANCE BCC试验的结果及意义
Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.
5
[Not Available].[无可用内容]
Ann Dermatol Venereol. 2018 Nov;145 Suppl 5:VS36-VS41. doi: 10.1016/S0151-9638(18)31257-2.
6
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.BOLT 研究:隆地替尼治疗基底细胞癌的 12 个月分析:一项评价晚期基底细胞癌患者接受 sonidegib 治疗的 II 期、随机、双盲研究。
J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5. doi: 10.1016/j.jaad.2016.02.1226. Epub 2016 Apr 7.
7
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.晚期基底细胞癌患者中刺猬通路抑制剂相关不良事件的特征与管理
Oncologist. 2016 Oct;21(10):1218-1229. doi: 10.1634/theoncologist.2016-0186. Epub 2016 Aug 10.
8
Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.索尼德吉用于治疗晚期基底细胞癌。
Front Oncol. 2020 Oct 30;10:582866. doi: 10.3389/fonc.2020.582866. eCollection 2020.
9
Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.Sonic Hedgehog 通路抑制在晚期基底细胞癌治疗中的应用。
Curr Treat Options Oncol. 2019 Nov 26;20(11):84. doi: 10.1007/s11864-019-0683-9.
10
Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.针对刺猬信号通路治疗局部晚期和转移性基底细胞癌
Curr Pharm Des. 2017;23(4):655-659. doi: 10.2174/1381612822666161208100325.

引用本文的文献

1
The Prognostic Value of the Hedgehog Signaling Pathway in Ovarian Cancer.刺猬信号通路在卵巢癌中的预后价值
Int J Mol Sci. 2025 Jun 19;26(12):5888. doi: 10.3390/ijms26125888.
2
Probing the biological efficacy and mechanistic pathways of natural compounds in breast cancer therapy via the Hedgehog signaling pathway.通过刺猬信号通路探究天然化合物在乳腺癌治疗中的生物学功效及作用机制途径。
J Pharm Anal. 2025 Apr;15(4):101143. doi: 10.1016/j.jpha.2024.101143. Epub 2024 Nov 13.
3
Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations.

本文引用的文献

1
Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity.低剂量维莫德吉作为局部晚期基底细胞癌完全缓解后的维持治疗:高效且毒性极小。
Dermatol Ther (Heidelb). 2020 Jun;10(3):465-468. doi: 10.1007/s13555-020-00371-1. Epub 2020 Apr 2.
2
Clues to primary vismodegib resistance lie in histology and genetics.原发性维莫德吉耐药的线索存在于组织学和遗传学中。
J Clin Pathol. 2020 Oct;73(10):678-680. doi: 10.1136/jclinpath-2020-206448. Epub 2020 Mar 26.
3
Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib.
揭示癌症干细胞治疗的未来:对新兴创新的叙事性探索。
Discov Oncol. 2025 Mar 22;16(1):373. doi: 10.1007/s12672-025-02102-4.
4
Unveiling novel susceptibility genes and drug targets for basal cell carcinoma by a cross-tissue transcriptome-wide association study.通过跨组织全转录组关联研究揭示基底细胞癌的新型易感基因和药物靶点。
Discov Oncol. 2025 Mar 10;16(1):288. doi: 10.1007/s12672-025-02019-y.
5
Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients.晚期基底细胞癌经检查点抑制后重新诱导使用刺猬信号通路抑制剂:12例患者系列研究
Cancers (Basel). 2022 Nov 7;14(21):5469. doi: 10.3390/cancers14215469.
维莫德吉治疗基底细胞癌的基因相关反应。
Sci Rep. 2020 Jan 27;10(1):1244. doi: 10.1038/s41598-020-58117-0.
4
Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib.基底细胞癌:多模式治疗及新辅助维莫德吉的作用
Autops Case Rep. 2019 Sep 27;9(4):e2019116. doi: 10.4322/acr.2019.116. eCollection 2019 Oct-Dec.
5
Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI).维莫德吉停药后的长期疗效以及使用皮肤病生活质量指数(DLQI)评估患者的健康相关生活质量。
Dermatol Ther (Heidelb). 2019 Dec;9(4):719-724. doi: 10.1007/s13555-019-00323-4. Epub 2019 Sep 10.
6
A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors.晚期基底细胞癌患者接受 Hedgehog 通路抑制剂治疗时的随访实用指南。
Oncologist. 2019 Aug;24(8):e755-e764. doi: 10.1634/theoncologist.2018-0924. Epub 2019 May 9.
7
Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report.维莫德吉成功治疗皮肤侵袭性基底细胞癌:一例报告
Perm J. 2018;22:17-181. doi: 10.7812/TPP/17-181.
8
A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.一项关于 Hedgehog 信号通路在基底细胞癌中作用的计算研究揭示了联合治疗的潜力和局限性。
BMC Cancer. 2018 May 18;18(1):569. doi: 10.1186/s12885-018-4451-1.
9
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.维莫德吉治疗晚期基底细胞癌患者:国际开放标签试验STEVIE的初步分析
Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5.
10
Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.涉及刺猬信号通路及其他方面的基底细胞癌发病机制与治疗
Mol Carcinog. 2017 Dec;56(12):2543-2557. doi: 10.1002/mc.22690. Epub 2017 Aug 22.